|
Market Closed -
Hong Kong S.E.
04:08:08 2026-10-30 am EDT
|
5-day change | 1st Jan Change | ||
| 7.865 HKD | -2.18% |
|
-5.75% | -6.70% |
| Oct. 30 | CSPC Pharma Begins Trial of Advanced Solid Tumor Drug in China | MT |
| Oct. 30 | CSPC Pharmaceutical Starts Phase I/II Trial of B7-H3 Cancer Drug in China | MT |
Company Valuation: CSPC Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 100,932 | 97,707 | 86,022 | 55,169 | 96,380 | 89,787 | - | - |
| Change | - | -3.19% | -11.96% | -35.87% | 74.7% | -6.84% | - | - |
| Enterprise Value (EV) 1 | 89,633 | 86,241 | 72,284 | 46,931 | 86,710 | 78,553 | 75,480 | 72,335 |
| Change | - | -3.79% | -16.18% | -35.07% | 84.76% | -9.41% | -3.91% | -4.17% |
| P/E | 14.7x | 14.1x | 13.5x | 12.1x | 21.8x | 8.85x | 13x | 12.2x |
| PBR | 3.17x | 2.86x | 2.39x | 1.62x | 2.56x | 2x | 1.87x | 1.73x |
| PEG | - | 14.13x | -1.73x | -0.5x | -9.88x | 0x | -0.4x | 1.84x |
| Capitalization / Revenue | 2.94x | 2.77x | 2.52x | 1.78x | 3.26x | 2.33x | 2.51x | 2.37x |
| EV / Revenue | 2.61x | 2.44x | 2.12x | 1.51x | 2.94x | 2.04x | 2.11x | 1.91x |
| EV / EBITDA | 9.5x | 9.43x | 8.39x | 6.22x | 12.1x | 5.72x | 7.87x | 6.77x |
| EV / EBIT | 10.7x | 10.8x | 9.77x | 7.68x | 15.6x | 6.44x | 9.38x | 8.53x |
| EV / FCF | 23.7x | 14.1x | 26.2x | 17.5x | 19.5x | 10.3x | 11.4x | 10.5x |
| FCF Yield | 4.22% | 7.11% | 3.82% | 5.71% | 5.12% | 9.72% | 8.8% | 9.55% |
| Dividend per Share 2 | 0.18 | 0.21 | 0.28 | 0.26 | 0.29 | 0.4603 | 0.3685 | 0.3921 |
| Rate of return | 2.13% | 2.56% | 3.86% | 5.44% | 3.44% | 5.85% | 4.69% | 4.98% |
| EPS 2 | 0.5773 | 0.5831 | 0.5376 | 0.3946 | 0.3859 | 0.889 | 0.6028 | 0.6428 |
| Distribution rate | 31.2% | 36% | 52.1% | 65.9% | 75.2% | 51.8% | 61.1% | 61% |
| Net sales 1 | 34,309 | 35,292 | 34,175 | 31,046 | 29,533 | 38,506 | 35,713 | 37,849 |
| EBITDA 1 | 9,431 | 9,148 | 8,615 | 7,547 | 7,168 | 13,737 | 9,592 | 10,689 |
| EBIT 1 | 8,366 | 7,952 | 7,400 | 6,113 | 5,564 | 12,191 | 8,050 | 8,479 |
| Net income 1 | 6,901 | 6,949 | 6,382 | 4,632 | 4,409 | 10,150 | 7,023 | 7,514 |
| Net Debt 1 | -11,298 | -11,467 | -13,738 | -8,238 | -9,670 | -11,234 | -14,307 | -17,453 |
| Reference price 2 | 8.470 | 8.200 | 7.260 | 4.780 | 8.430 | 7.865 | 7.865 | 7.865 |
| Nbr of stocks (in thousands) | 11,916,370 | 11,915,520 | 11,848,756 | 11,541,665 | 11,433,025 | 11,416,025 | - | - |
| Announcement Date | 3/22/22 | 3/22/23 | 3/20/24 | 3/28/25 | 3/25/26 | - | - | - |
1HKD in Million2HKD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 8.85x | 2.04x | 5.72x | 5.85% | 11.44B | |
| 41.42x | 14.04x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 36.71x | 8.6x | 17.71x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 106.24x | 6.06x | 25.8x | 2.28% | 369B | |
| 23.19x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.47x | 4.89x | 13.59x | 1.77% | 290B | |
| 29.55x | 7.53x | 13.48x | 2.16% | 252B | |
| -41.18x | 7.46x | 46.76x | 1.93% | 212B | |
| Average | 29.10x | 6.86x | 20.05x | 2.39% | 427.34B | |
| Weighted average by Cap. | 37.08x | 8.81x | 22.77x | 1.7% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 1093 Stock
- Valuation CSPC Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
